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Patient and researcher perspectives on facilitating patient and public involvement in 
rheumatology research 
INTRODUCTION 
The Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE) is a 
partnership between researchers at Newcastle University, the University of Birmingham and the 
University of Glasgow. Established in 2013, it is funded for 5 years with a grant of £2.5 million 
from Arthritis Research UK and a further £4 million pledged by the three universities. 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition that affects the joints 
and internal organs. Synovial inflammation can cause cartilage and bone damage with resultant 
joint destruction and associated disability. RACE aims to identify biological mechanisms 
involved in the initiation of RA and its progression to a chronic disease, and to identify novel 
therapeutic targets for control and cure. 
It has long been recognised that patients’ experience complements researchers’ skills (Hewlett 
et al, 2006). At the outset of the RACE project, it was agreed that patient engagement and 
involvement was crucial to facilitate the translation of research undertaken by the centre into 
public benefit. This paper reports on a  conference held at the University of Birmingham in 
January 2016 to bring together patient and public involvement (PPI) representatives from each 
hub, and to provide patients’ and carers’ perspectives on the following questions: 
 What should research charities focus their spending on? 
 How can people with RA influence the research agenda? 
 What are the best ways for scientists to feed back to patients, relatives and carers about 
research findings? 
 
BACKGROUND 
PPI in all stages of the research process is advocated by funding bodies and policy makers as a 
way of enhancing the relevance, quality and efficiency of research (INVOLVE, 2012; NIHR, 
2015). The input of PPI partners has been shown to enhance design of clinical trials (Brett et al, 
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2012), development of patient relevant research ideas (Bergsten et al,  2014),  agenda setting 
(de Wit et al, 2013) and developing appropriate patient reported outcomes for clinical trials (de 
Wit et al, 2015). Evidence suggests that patients identify different treatment priorities to 
clinicians (Kwoh et al, 2001; da Silva et al, 2010). This reinforces the case for involving patients 
in the design of research to ensure that their priorities are addressed, and to improve the quality 
and impact of that research. 
Patients have been involved in rheumatology research at each of the three hubs prior to the 
inception of RACE; therefore the project offers a unique opportunity to bring together patient 
partners from each of the hubs to share experiences and best practice. Details of these groups 
can be found in Table 1. 
RACE PATIENT CONFERENCE  
The conference was attended by two patient research partners from Birmingham, five from 
Glasgow and six from Newcastle, 11 of whom completed a questionnaire prior to the 
conference to describe their existing experience of research involvement.  The participants’ 
previous involvement in research activities is summarized in Tables 2 and 3. Patient partners 
who attended the conference had limited previous research involvement but were enthusiastic 
to become involved, as evidenced by their attendance and comments at the conference. 
Respondents were asked to describe any benefits they had experienced or anticipated from 
involvement in research. Similar responses were obtained from those who had previous 
experience of PPI and those who had none. These can be summarised as: 
 A better understanding of current research 
 An increased knowledge of the disease and how to alleviate symptoms 
 An opportunity to support research and ensure it is targeted at patient needs 
 Improved dissemination among patient groups  
 Access to the latest research 
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Respondents were also asked to describe any difficulties they had experienced or anticipated 
from PPI in research. Many had encountered or anticipated no difficulties, although some raised 
concerns about the time commitment required, the use of technical language or the possibility 
that deterioration in their health might result in them withdrawing or reducing their involvement.  
Clinicians and researchers from each hub were also present, along with the RACE project 
manager and a representative from Arthritis Research UK. Following an introductory 
presentation on PPI and the existing contribution of patient partners to rheumatology research 
at each hub, delegates split into groups to facilitate discussion and debate of the main topic 
areas. A third group of scientific researchers and clinicians affiliated with the University of 
Birmingham met separately to discuss the same questions. The three groups were then brought 
together to share key discussion points, which are summarized below under each topic. 
Outcomes from group discussions 
What should research charities focus their spending on?  
There were some key differences between the views expressed by patient representatives and 
the expectations of researchers and clinicians. The latter group felt patients would wish 
resources to be directed towards development of new treatments; particularly for those with 
longstanding, difficult to treat RA, who are increasingly described as becoming a neglected 
group in terms of research priorities.  
However, patient representatives were of the opinion that research to identify and evaluate new 
treatments for RA would be driven by the pharmaceutical industry, and that charity funding 
should be focussed on understanding the biological processes that cause disease and on 
predicting response to treatment. Other priorities for patients included: 
 Evaluation of the effectiveness of self-management strategies 
 Development of treatments for RA-related fatigue  
 The development of educational and awareness-raising initiatives about RA.  
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The researchers/clinicians anticipated that patients’ priorities would feature research into the 
effectiveness of non-pharmacological approaches for the management of RA. The patient group 
agreed there was need for evidence of the effectiveness of such approaches. Patient 
representatives also reported that a focus on the therapeutic effectiveness of treatments was 
more desirable than a focus on their cost-effectiveness. 
How can people with rheumatoid arthritis influence the research agenda? 
The importance of PPI in research, and research agenda setting, was agreed by all three 
discussion groups. The challenges of involving patients in basic laboratory-based research were 
also discussed, with particular reference to the language gap between patients and 
researchers. Examples of successful approaches to this problem in previous projects were 
shared, such as the development of a glossary for PPI partners taking part in the European 
Union’s FP7 project ‘EuroTEAM’ (Towards Early diagnosis and biomarker validation in Arthritis 
Management: www.team-arthritis.eu). Many patient partners perceived opportunities to become 
involved in research to be limited, and reported a lack of public awareness of such 
opportunities, and of the benefits of becoming involved. Benefits that were suggested included 
the ability to access the latest research findings and to engage with researchers, as well as the 
opportunity to “give something back” for care received by contributing to the research process. It 
was suggested that access to such benefits should be publicised and routinely available to all 
patients. 
A concern was raised by patients that those who become involved with research may not be 
representative of the wider patient group, and often develop extensive research expertise, 
leading to a possible loss of perspective. It was agreed that it would be important to identify 
ways to widen access to research involvement in order to mitigate this. Patient representatives 
commented that it is not always straightforward for patients to attend research meetings in 
person, and opportunities to learn about involvement and contribute to research in other ways 
(e.g. via email or Skype) were welcomed. 
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The clinicians and researchers acknowledged the variety of opportunities for involving people 
throughout the research cycle (Fig 1), and highlighted the responsibility of researchers to be 
aware of the benefits of PPI, and to provide patients with comprehensive information about 
current research and future possibilities in order for them to be able to make fully informed 
suggestions and choices about research priorities. It was suggested that in this way the 
research cycle (Fig 1) should be seen as a virtuous cycle, where effective dissemination of 
research findings to patients facilitates the input of patients to the research agenda, and their 
ongoing engagement with the research process. This was echoed by patient representatives 
who suggested that patient involvement should be an important aspect of training of 
researchers, including those involved in basic, laboratory-based science. 
What are the best ways for scientists to feed back to patients, relatives and carers about 
their research findings? 
All groups agreed that patients could very usefully be involved in the development and 
distribution of resources to communicate research findings. Furthermore, it was felt that groups 
such R2P2, PIRR and PIMS or other patient organised groups were an important mechanism 
for the dissemination of research findings.  
It was suggested by patient representatives that it might be helpful to conceptualise three tiers 
of target audience: patients already actively engaged with research; patients who are not 
engaged, and the wider public. Thus dissemination to local groups who can then cascade 
information via existing networks was perceived to be a useful approach. There was a strong 
consensus that this kind of dissemination activity needed to occur at regular intervals with a 
well-publicised timetable.  
Patient representatives involved in local groups suggested that they would value a database of 
local researchers who were willing to present their work to patients, along with opportunities to 
link with websites or mail-outs associated with other local and national patient groups.  Whilst 
the importance of increased opportunities for social networking in this context was discussed, 
patient representatives felt that traditional media should not be neglected, as many patients do 
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not use the internet or social media. Several patients suggested that patient-friendly posters 
displayed in outpatient settings could be an effective route for local dissemination. In the 
researchers’ group there was discussion about whether clinicians or scientists were best placed 
to disseminate research findings to patients. Some concern was expressed by non-clinical 
researchers that there would be a perception on the part of patients that all researchers would 
have clinical knowledge. However several non-clinical researchers described very positive 
experiences of face to face dissemination to patient groups, although it was acknowledged that 
preparatory work was necessary to ensure appropriate use of non-technical language and 
management of patients’ expectations in relation to the researcher’s ability to answer clinical 
questions. 
Patient representatives stressed the importance of communicating with patient partners 
throughout the research cycle, as well as on completion of specific research projects, and 
highlighted the need for training for researchers from an early stage of their career to provide 
them with skills in the communication of research findings to patients and the wider public.  
It was suggested that university press offices could be better engaged with scientists, and that 
there was a potentially useful role for patients to be involved in the identification of tractable 
items arising from research findings that might be seen as newsworthy. 
 
CONCLUDING REMARKS 
In summary, there was wide agreement about the benefits of PPI in rheumatology research for 
all stakeholders. It was also generally agreed that research into the basic disease mechanisms 
of RA and prediction of disease outcome should be important priorities, though 
scientists/clinicians had expected patients to place greater emphasis on the development of 
new treatments and non-pharmacological approaches. Participants shared their experiences of 
dissemination activities and identified effective strategies and opportunities for patient 
involvement in this context. An important role for patient groups and networks was identified in 
this context. We acknowledge that participating patients had previously expressed an interest in 
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involvement with the RACE project, and their views may not represent those of all patients with 
RA. Further research is necessary to ascertain variations in patient perspectives in this context. 
The RACE patient conference has identified key issues that should be addressed to facilitate 
patient involvement in rheumatology research: 
 Increasing awareness of PPI and involvement opportunities  
 Widening access to research involvement 
 Increasing involvement of patients in research priority setting 
 Training for researchers on the benefits of PPI and identification of involvement 
opportunities 
 Training for researchers in the communication of research findings to patients 
 Improving communication between researchers and patient groups 
 Fostering robust networks for communication between researchers, patient groups, 
uninvolved patients and the wider public.  
 Increasing opportunities for sharing best practice in patient involvement and the 
dissemination of research findings to patients, carers, relatives and the wider public. 
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Table 1.  Patient involvement in rheumatology research 
Birmingham The Birmingham Rheumatology Research Patient Partnership (R2P2) 
www.bham.ac.uk/r2p2 is an established partnership between people with 
rheumatoid arthritis and/or Sjögren’s syndrome and rheumatology 
researchers at the University of Birmingham, Sandwell and West 
Birmingham Hospitals NHS Trust and University Hospitals Birmingham NHS 
Foundation Trust. It was officially launched in October 2014, building on the 
success of patient partner panels that had been established to support 
individual research projects. 
Members of R2P2 are actively involved in all aspects of the research 
process, including the development of grant applications, the design of study 
procedures and of participant facing research materials, the development of 
informational resources and the dissemination of research findings via 
patient networks and support groups. Patient partners are co-authors on 
papers including those related to the development of international research 
recommendations (Gerlag et al, 2012); the development of patient 
questionnaires (Stack et al, 2014) and patient-initiated research to determine 
why people with symptoms of rheumatoid arthritis delay seeking help 
(Tiwana et al, 2015). 
 
Glasgow The Glasgow Patient Involvement in Rheumatology Research (PIRR) is in 
the early stages of its development with patient representation on clinical 
trial steering groups and further recruitment of patient research partners 
underway. Identification of possible patient partners has been through 
NRAS, Arthritis Care and clinicians. There has been informal patient 
involvement for a number of years, while research is a standing item on the 
agenda of the Patient Engagement sub-group (which includes patient 
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representatives) of the Rheumatology Managed Clinical Network of NHS 
Greater Glasgow and Clyde. 
 
Newcastle The Newcastle Public Involvement in Musculoskeletal Services (PIMS) 
Group held its first formal meeting in March 2015. This joint project between 
Newcastle University and the Newcastle-upon-Tyne Hospitals NHS 
Foundation Trust has two main objectives:  
 To involve service users and carers in improving the quality of services 
and making services more responsive to the needs of the individuals 
who use them;  
 To involve service users and carers in different aspects of research 
projects at Newcastle upon Tyne Hospitals NHS Foundation Trust, 
providing a forum for researchers and the public / patient community to 
formally engage with each other. 
Researchers also discuss future projects and feedback results with existing 
patient groups, including NESSA (North East Sjögren’s Syndrome 
Association) and the local NRAS group. 
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Table 2. Frequency of patient research partners’ previous experience of involvement in 
research projects 
Activity Never 1 research 
project 
2-5 research 
projects 
More than 5 
research projects 
Developing grant 
application 
9 1 1 0 
Offering advice as 
a member of a 
project steering 
group 
9 0 1 1 
Developing 
research materials 
e.g. patient 
information sheets 
9 0 2 0 
Writing of research 
reports 
10 0 1 0 
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Table 3. Frequency of patient research partners’ previous experience of involvement in 
research events 
Events Never 1 event 2-5 events More than 5 
events 
Setting research 
priorities 
10 1 0 0 
Sharing research 
findings with the 
general public 
9 0 2 0 
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Figure 1 - Ways in which people can be involved in the research cycle (INVOLVE, 2012) 
 
 
 
